Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07523438 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Effect of Intranasal Dexmedetomidine on the Incidence of Emergence Agitation in Children Undergoing Strabismus Surgery

StatusRecruiting
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 2 months later Sep 1, 2026 → Nov 1, 2026
See other at-risk trials from Alexandria University

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary completion pushed from Sep 1, 2026 to Nov 1, 2026 Show 4 more changesShow less
    • Enrollment increased: 120 → 150 participants
    • Eligibility criteria expanded, about 7 words
    • Study description expanded, about 242 words
    • Publications: details revised at 1 of 1 entry
  2. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Dexmedetomidine is a selective a-2 adrenergic agonist that provides sedative and analgesic effects. Intranasal dexmedetomidine has a slower and gradual onset compared to intravenous injection , with low incidence of nasal discomfort. Dexmedetomidine was tested at various doses and modes of administration, as well as different types of surgery and co-anesthetic drugs, as a single injection or continuous infusion. The authors have not agreed on the ideal clinical dose. The hypothesis is that intranasal dexmedetomidine 3mcg /kg will decrease the incidence of emergence agitation after strabismus surgery than dexmedetomidine 2 mcg/kg
Trial Details
NCT Number NCT07523438
Lead Sponsor Alexandria University
Conditions
(from sponsor)		 Dexmedetomidine, Emergence Agitation
Related terms Emergence Delirium
Enrollment 150 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov